Krka, d. d.
KRK
Peringkat dalam Saham
#2129
Krka, d. d. is a leading generic pharmaceutical enterprise primarily involved... Krka, d. d. is a leading generic pharmaceutical enterprise primarily involved in the research, production, promotion, and sale of various pharmaceutical goods. Its market presence spans Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and numerous other international territories. The company's offerings are categorized into prescription medications, over-the-counter products, and veterinary health solutions. Its prescription drug pipeline targets a broad spectrum of medical conditions, including cardiovascular disorders, gastrointestinal issues, central nervous system ailments, pain management, anti-infective treatments, conditions affecting blood and blood-forming organs, urological problems, diabetes, and oncology. The array of non-prescription items includes products for oral and throat care, cough and cold remedies, analgesics, nasal preparations, vitamin and mineral supplements, products designed to enhance cerebral and peripheral circulation, digestive aids, and various general healthcare products. Furthermore, Krka supplies animal health products such as anti-infectives, antiparasitics, and other specialized formulations for both livestock and companion animals. Beyond its pharmaceutical operations, the company also provides health resort and tourist services. Krka, d. d. was established in 1954 and has its corporate headquarters in Novo Mesto, Slovenia.
Harga Saham
$318.12
Terakhir disinkronkan: 2026-10-20
Kapitalisasi Pasar
$9.63B
Perubahan (1 hari)
0.18%
Perubahan (1 tahun)
29.20%
Negara
SI
Perdagangan Krka, d. d. (KRK)
Kategori
Healthcare
Laba untuk Krka, d. d. (KRK)
Laba pada Jun 2026 TTM: $613.56M
Menurut laporan keuangan terbaru dari Krka, d. d., laba saat ini perusahaan adalah $613.56M. Pada tahun 2023, perusahaan memperoleh laba sebesar $405.84M, penurunan dibandingkan dengan laba tahun 2022 sebesar $464.55M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Krka, d. d. dari 2010 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $613.56M | 40.70% |
| 2024 | $436.08M | 7.45% |
| 2023 | $405.84M | -12.64% |
| 2022 | $464.55M | 12.72% |
| 2021 | $412.12M | -0.18% |
| 2020 | $412.85M | 29.40% |
| 2019 | $319.06M | 37.06% |
| 2018 | $232.79M | 10.12% |
| 2017 | $211.39M | 72.75% |
| 2016 | $122.37M | -37.64% |
| 2015 | $196.22M | -7.49% |
| 2014 | $212.12M | -23.39% |
| 2013 | $276.88M | 10.18% |
| 2012 | $251.29M | -2.93% |
| 2011 | $258.87M | -8.40% |
| 2010 | $282.60M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 187.59% |
IN
|
